Epratuzumab
Humanized (from mouse) | |
|---|---|
| Target | CD22 |
| Clinical data | |
| Trade names | LymphoCide |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Epratuzumab (planned trade name LymphoCide) is a
Clinical trials
A clinical trial for relapsed adult acute lymphoblastic leukemia (ALL) has reported initial results.[3]
Results have been published for a phase II trial in untreated follicular lymphoma.[3]
Early results from a phase II trial for Diffuse large B-cell lymphoma (DLBCL) were encouraging.[3][4]
The manufacturers in August 2009 announced success in early trials against SLE,
July 2015 : Both phase III trials (EMBODY1/2) for SLE failed to meet their primary endpoint.[6]
Mechanism of action
Epratuzumab binds to the glycoprotein
Elevated CD22 and other B-cell receptor (BCR) proteins are associated with SLE. "Epratuzumab's mechanism of action transfers these BCR proteins to helper cells called effector cells which reduces B-cell destruction and epratuzumab's impact on the body's immune system"[6] via a process called trogocytosis.[3] Other SLE therapies destroy B-cells which compromises the immune system.
References
- PMID 14506197.
- PMID 16033839.
- ^ a b c d "Epratuzumab". Archived from the original on 2015-08-15. Retrieved 2015-08-01.
- PMID 21673350.
- ^ "UCB and Immunomedics Announce Positive Results for Epratuzumab Phase IIb Study in Systemic Lupus Erythematosus (SLE)". Reuters. Archived from the original on 2009-10-13.
- ^ a b "Epratuzumab flunks two Phase 3 studies; Immunomedics plummets 42% premarket". Seeking Alpha. 28 July 2015.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |